These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 27297449)

  • 1. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phantom studies and clinical application of high resolution, image reconstruction using (18)F-fluoromethylcholine PET/CT for prostate cancer.
    Zielinski A; Behrendt FF; Verburg FA; Mottaghy FM; Krohn T
    Hell J Nucl Med; 2014; 17(3):194-9. PubMed ID: 25397625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Loidl W; Broinger G; Stoiber F; Foglman I; Langsteger W
    Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1766-74. PubMed ID: 18465129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer.
    Beauregard JM; Williams SG; Degrado TR; Roselt P; Hicks RJ
    J Med Imaging Radiat Oncol; 2010 Aug; 54(4):325-32. PubMed ID: 20718912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
    Zattoni F; Agostini E; Cattaneo F; Maruzzo M; Basso U; Zattoni F; Evangelista L
    Clin Imaging; 2017; 43():110-116. PubMed ID: 28278446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.
    Pfluger T; Melzer HI; Schneider V; La Fougere C; Coppenrath E; Berking C; Bartenstein P; Weiss M
    Eur J Nucl Med Mol Imaging; 2011 May; 38(5):822-31. PubMed ID: 21210112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.
    Beheshti M; Imamovic L; Broinger G; Vali R; Waldenberger P; Stoiber F; Nader M; Gruy B; Janetschek G; Langsteger W
    Radiology; 2010 Mar; 254(3):925-33. PubMed ID: 20177103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-Dimensional Image Fusion of
    Yu Y; Zhang WB; Liu XJ; Guo CB; Yu GY; Peng X
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1301.e1-1301.e15. PubMed ID: 28320612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT in lung cancer: Influence of contrast medium on quantitative and clinical assessment.
    Behrendt FF; Temur Y; Verburg FA; Palmowski M; Krohn T; Pietsch H; Kuhl CK; Mottaghy FM
    Eur Radiol; 2012 Nov; 22(11):2458-64. PubMed ID: 22661058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of
    Palard-Novello X; Beuzit L; Gambarota G; Le Jeune F; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Saint-Jalmes H
    Ann Nucl Med; 2019 Jan; 33(1):47-54. PubMed ID: 30219990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
    Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
    J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiphase CT scanning and different intravenous contrast media concentrations in combined F-18-FDG PET/CT: Effect on quantitative and clinical assessment.
    Rebière M; Verburg FA; Palmowski M; Krohn T; Pietsch H; Kuhl CK; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2012 Aug; 81(8):e862-9. PubMed ID: 22591760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contrast medium injection protocol adjusted for body surface area in combined PET/CT.
    Behrendt FF; Rebière M; Goedicke A; Pietsch H; Palmowski K; Kuhl CK; Mottaghy FM; Verburg FA
    Eur Radiol; 2013 Jul; 23(7):1970-7. PubMed ID: 23423636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
    Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer.
    Kjölhede H; Ahlgren G; Almquist H; Liedberg F; Lyttkens K; Ohlsson T; Bratt O
    BJU Int; 2012 Nov; 110(10):1501-6. PubMed ID: 22502982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.